Total Payments
$1,634
2024 Payments
$162.08
Companies
13
Transactions
35
Medicare Patients
25,300
Medicare Billing
$13.2M
Payment Breakdown by Category
Food & Beverage$1,568 (95.9%)
Other$66.68 (4.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,568 | 34 | 95.9% |
| Entertainment | $66.68 | 1 | 4.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $248.90 | 7 | $0 (2023) |
| Alcon Laboratories Inc | $218.84 | 2 | $0 (2017) |
| ABBVIE INC. | $180.98 | 5 | $0 (2024) |
| Allergan, Inc. | $148.78 | 7 | $0 (2021) |
| Astellas Pharma US Inc | $146.50 | 5 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $138.18 | 1 | $0 (2018) |
| NotalVision | $127.87 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $125.98 | 1 | $0 (2023) |
| Kala Pharmaceuticals, Inc. | $124.80 | 1 | $0 (2019) |
| Optos, Inc. | $66.68 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $162.08 | 5 | Astellas Pharma US Inc ($100.79) |
| 2023 | $303.01 | 6 | Regeneron Healthcare Solutions, Inc. ($125.98) |
| 2022 | $91.64 | 4 | ABBVIE INC. ($67.76) |
| 2021 | $67.41 | 3 | Allergan, Inc. ($67.41) |
| 2020 | $17.39 | 1 | Allergan, Inc. ($17.39) |
| 2019 | $190.05 | 4 | Kala Pharmaceuticals, Inc. ($124.80) |
| 2018 | $184.83 | 3 | Sun Pharmaceutical Industries Inc. ($138.18) |
| 2017 | $617.81 | 9 | Alcon Laboratories Inc ($218.84) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/13/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.02 | General |
| Category: Ophthalmology | ||||||
| 07/15/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.54 | General |
| Category: Ophthalmology | ||||||
| 07/10/2024 | Harrow Eye, LLC | IHEEZO (Drug) | Food and Beverage | In-kind items and services | $39.92 | General |
| Category: OPTOMETRY | ||||||
| 05/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: EYE CARE | ||||||
| 05/13/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $32.23 | General |
| Category: Ophthalmology | ||||||
| 11/21/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $27.77 | General |
| 08/16/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $17.94 | General |
| 06/30/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/09/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $125.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/10/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/14/2023 | AbbVie Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $91.85 | General |
| Category: EYE CARE | ||||||
| 12/12/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/06/2022 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: RETINA | ||||||
| 11/29/2022 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: RETINA | ||||||
| 04/07/2022 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: RETINA | ||||||
| 12/23/2021 | Allergan, Inc. | VUITY (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/15/2021 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: RETINA | ||||||
| 04/07/2021 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: RETINA | ||||||
| 03/13/2020 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: RETINA | ||||||
| 09/25/2019 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Ophthalmology | ||||||
| 06/27/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/29/2019 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: OCULAR | ||||||
| 04/26/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/15/2018 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Ophthalmology | ||||||
| 05/11/2018 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 6,639 | 39,122 | $17.9M | $4.3M |
| 2022 | 17 | 6,441 | 19,488 | $10.9M | $3.4M |
| 2021 | 20 | 6,592 | 19,600 | $7.7M | $3.1M |
| 2020 | 17 | 5,628 | 16,707 | $4.8M | $2.5M |
Total Patients
25,300
Total Services
94,917
Medicare Billing
$13.2M
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 283 | 2,974 | $7.4M | $2.1M | 27.7% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 45 | 19,800 | $2.5M | $571,519 | 23.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,638 | 4,319 | $1.6M | $456,063 | 28.9% |
| J3590 | Unclassified biologics | Office | 2023 | 117 | 166 | $1.2M | $392,152 | 32.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 394 | 2,115 | $1.3M | $235,975 | 18.1% |
| 92134 | Imaging of retina | Office | 2023 | 1,687 | 4,368 | $2.0M | $155,519 | 7.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 33 | 593 | $593,000 | $111,530 | 18.8% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 26 | 305 | $305,000 | $65,685 | 21.5% |
| J3490 | Unclassified drugs | Office | 2023 | 22 | 34 | $193,000 | $61,606 | 31.9% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 1,413 | 3,214 | $369,610 | $42,543 | 11.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 249 | 249 | $117,030 | $34,067 | 29.1% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 84 | 260 | $184,992 | $18,660 | 10.1% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 17 | 17 | $54,213 | $17,632 | 32.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 125 | 131 | $48,863 | $16,083 | 32.9% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 405 | 468 | $58,500 | $9,441 | 16.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 33 | 37 | $9,583 | $3,039 | 31.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 17 | 17 | $7,327 | $1,803 | 24.6% |
| 92250 | Photography of the retina | Office | 2023 | 35 | 35 | $6,790 | $1,066 | 15.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 16 | 20 | $5,260 | $847.88 | 16.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 234 | 2,902 | $5.5M | $2.1M | 37.9% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 1,469 | 3,769 | $1.1M | $421,047 | 38.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 54 | 1,465 | $1.1M | $327,501 | 29.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 380 | 1,846 | $1.1M | $206,513 | 18.0% |
| 92134 | Imaging of retina | Office | 2022 | 1,596 | 4,331 | $1.2M | $155,593 | 12.6% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 1,301 | 3,271 | $274,919 | $44,354 | 16.1% |
About Dr. Daniel Berinstein, M.D
Dr. Daniel Berinstein, M.D is a Ophthalmology healthcare provider based in Chevy Chase, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366416406.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Berinstein, M.D has received a total of $1,634 in payments from pharmaceutical and medical device companies, with $162.08 received in 2024. These payments were reported across 35 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($1,568).
As a Medicare-enrolled provider, Berinstein has provided services to 25,300 Medicare beneficiaries, totaling 94,917 services with total Medicare billing of $13.2M. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Retina Specialist
- Location Chevy Chase, MD
- Active Since 02/15/2006
- Last Updated 11/26/2019
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1366416406
Products in Payments
- OZURDEX (Drug) $307.00
- Lucentis (Biological) $185.55
- BromSite (bromfenac ophthalmic solution) 0.075% (Drug) $138.18
- ForeseeHome (Device) $127.87
- EYLEA (Biological) $125.98
- INVELTYS (Drug) $124.80
- NGENUITY (Device) $118.33
- Izervay (Drug) $100.79
- ReSTOR (Device) $100.51
- California (Device) $66.68
- BEOVU (Drug) $44.24
- IHEEZO (Drug) $39.92
- Vabysmo (Drug) $39.47
- VABYSMO (Drug) $23.88
- VUITY (Drug) $22.76
- ACTHAR (Biological) $22.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Chevy Chase
Thomas Clinch, Md, MD
Ophthalmology — Payments: $248,965
Ophthalmology $248,965
Dr. Anand Mantravadi, M.d, M.D
Ophthalmology — Payments: $135,695
Ophthalmology $135,695
Dr. Hylton Mayer, M. D, M. D
Ophthalmology — Payments: $96,221
Ophthalmology $96,221
Dr. Brian Do, M.d, M.D
Ophthalmology — Payments: $94,769
Ophthalmology $94,769
Neil Martin, Md, MD
Ophthalmology — Payments: $13,932
Ophthalmology $13,932
Dr. Kenneth Schor, M.d, M.D
Ophthalmology — Payments: $13,226
Ophthalmology $13,226